Reimagining Biopharma Supply Chain

Webinar

Can drug developers and regulators create a sustainable culture that allows the biopharma industry to continue to work with the accelerated model adopted during the COVID-19 pandemic, or will industry burnout ensue?

Programmed by Economist Impact and sponsored by Merck The art of the possible: reimagining the biopharmaceutical supply chain will examine what leaders in the biopharmaceutical supply chain must do to steer their businesses through a time of rapid change and ongoing disruption, and identify synergies and efficiencies to bring drugs to market more effectively.